Interrogating glioma-M2 macrophage interactions identifies Gal-9/Tim-3 as a viable target against <i>PTEN</i>-null glioblastoma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35857445.
- Also identified by DOI 10.1126/sciadv.abl5165 and PMC identifier 9269888.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Genomic alteration can reshape tumor microenvironment to drive tumor malignancy. However, how <i>PTEN</i> deficiency influences microenvironment-mediated cell-cell interactions in glioblastoma (GBM) remains unclear. Here, we show that <i>PTEN</i> deficiency induces a symbiotic glioma-M2 macrophage interaction to support glioma progression. Mechanistically, <i>PTEN</i>-deficient GBM cells secrete high levels of galectin-9 (Gal-9) via the AKT-GSK3β-IRF1 pathway. The secreted Gal-9 drives macrophage M2 polarization by activating its receptor Tim-3 and downstream pathways in macrophages. These macrophages, in turn, secrete VEGFA to stimulate angiogenesis and support glioma growth. Furthermore, enhanced Gal-9/Tim-3 expression predicts poor outcome in glioma patients. In GBM models, blockade of Gal-9/Tim-3 signaling inhibits macrophage M2 polarization and suppresses tumor growth. Moreover, α-lactose attenuates glioma angiogenesis by down-regulating macrophage-derived VEGFA, providing a novel antivascularization strategy. Therefore, our study suggests that blockade of Gal-9/Tim-3 signaling is effective to impair glioma progression by inhibiting macrophage M2 polarization, specifically for <i>PTEN</i>-null GBM.
Medical subject headings
- Glioblastoma
- Glioma